Syngene International announced late last night that its subsidiary Syngene USA has successfully acquired its first biologics site in the USA from Emergent Manufacturing Operations Baltimore, LLC for $36.5 million. This acquisition will expand Syngene’s single-use bioreactor capacity to 50,000L for large molecule discovery, development, and manufacturing services.
In the third quarter, Syngene reported a profit after tax of ₹131 crore, up from ₹112 crore in the same period last year. Revenue from operations saw an 11% year-on-year increase to ₹944 crore and a 6% sequential growth from the previous year’s quarter.
Despite this positive development, shares of Syngene ended flat on the NSE at ₹704.55.
The company’s acquisition is expected to enhance its capabilities in the biologics sector and strengthen its position in the market.
Published on March 20, 2025.
